Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ascada Health PC

Neither a doctor nor a teaching hospital

Research payments

$1,048,274

69 payments

Through program year 2025, Ascada Health PC is reported as receiving $1,048,274 in research payments, across 69 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $68,625 22
2024 Research $433,957 20
2023 Research $303,014 25
2022 Research $74,317 1
2021 Research $168,360 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. Pfizer Inc. $544,468 45 payments
  2. Novartis Pharmaceuticals Corporation $242,678 2 payments
  3. Quidel Corporation $221,327 6 payments
  4. Moderna TX, Inc. $33,302 15 payments
  5. GlaxoSmithKline, LLC. $6,500 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $430,291 21 payments
  2. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 (The Empathy Trial) $168,360 1 payment
  3. CS-0393-03: Lyra Direct SARS-CoV-2 and Lyra SARS-CoV-2 Validation Study $164,327 5 payments
  4. An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $94,489 23 payments
  5. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 $74,317 1 payment
  6. QuickVue At-Home COVID-19 Reproducibility Study $57,000 1 payment
  7. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $33,302 15 payments
  8. An Interventional Efficacy and Safety Phase 3 Randomized Doubleblind 3Arm Study to Investigate Ibuzatrelvir in Adults With Symptomatic Covid19 Who Are Severely Immunocompromised $19,687 1 payment
  9. A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $6,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record